1.
2.
3.
As US measles cases rise, biotech firms start developing new treatments
(arstechnica.com)
5.
Argenx to Buy Forte Biosciences for $2.2 Billion
(feeds.content.dowjones.io)
6.
The Scientist With 1,000 Patents Fueling a Drug Powerhouse
(feeds.content.dowjones.io)
7.
The Download: an organ transplant breakthrough, and homegrown Chinese chips
(technologyreview.com)
8.
AI-redesigned starting points and outcomes enhance protein evolution
(feeds.nature.com)
10.
11.
DNA-shredding CRISPR enzyme takes aim at cancer cells
(feeds.nature.com)
12.
U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China
(feeds.content.dowjones.io)
13.
Novartis to Buy Myricx Bio for Up to $1.5 Billion
(feeds.content.dowjones.io)
14.
Anthropic wants to develop its own drugs
(theverge.com)
15.
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
(feeds.content.dowjones.io)
16.
17.
Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million
(feeds.content.dowjones.io)
18.
How Seriously Should We Take The Threat of Mirror Life?
(gizmodo.com)
19.
Germany’s Merck to Boost Lab-Tools Business With $11 Billion Bio-Techne Deal
(feeds.content.dowjones.io)
20.
22.
Ending respiratory infections
(news.ycombinator.com)
23.
Ending All Respiratory Infections
(news.ycombinator.com)
24.
A 1970s patent that changed the course of commercial biotechnology
(feeds.nature.com)
25.
26.
The Download: “reprogramming” aging, and the hidden sense of interoception
(technologyreview.com)
27.
Why “reprogramming” is the buzziest approach to reversing aging right now
(technologyreview.com)
28.
29.
30.
J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge?
(feeds.content.dowjones.io)
Today's top topics:
apple